2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Textor, S. C. Search for Related Content PubMed PubMed Citation Articles by Textor, S. C.

Ischemic Nephropathy: Where Are We Now?

Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota

Correspondence to Dr. Stephen C. Textor, W9A, Mayo Clinic, Rochester, MN 55905. Phone: 507-284-4841; Fax: 507-284-1161; E-mail: textor.stephen{at}mayo.edu

ABSTRACT. Identification and reversing the loss of kidney function beyond occlusive disease of the renal arteries poses a major clinical challenge. Recent studies indicate that atherosclerotic renal artery stenosis develops as a function of age and is commonly associated with other microvascular disease, including nephrosclerosis and diabetic nephropathy. The risks of renal artery stenosis are related both to declining kidney function and to accelerated cardiovascular disease, with increased morbidity and mortality. Newer drugs, including agents that block the renin-angiotensin system, have improved the level of BP control for renovascular hypertension. Progressive renovascular disease during medical therapy can produce refractory hypertension, congestive heart failure, and renal failure with tubulointerstitial fibrosis. Recent studies indicate a complex interplay of oxidative stress, endothelial dysfunction, and activation of fibrogenic cytokines as a result of experimental atherosclerosis and renal hypoperfusion. Advances in imaging and interventional devices offer major new opportunities to prevent progressive loss of kidney function. Recent series indicate that although 25 to 30% of patients with impaired renal function can recover glomerular filtration after revascularization, many have no apparent change in kidney function and 19 to 25% experience a significant loss of kidney function, in some cases as a result of atheroemboli. To select patients who are most likely to benefit from vascular intervention, clinicians should understand the pathophysiology of developing ischemic nephropathy and the potential hazards of revascularization in the setting of diffuse atherosclerotic disease. Further research should be directed toward identification of critical disease, regulation of fibrogenesis, and the interaction with other atherosclerotic processes.

This article has been cited by other articles:

				M. A. Creager, C. J. White, W. R. Hiatt, M. H. Criqui, S. C. Josephs, M. J. Alberts, W. H. Pearce, B. H. Gray, and K. J. Rocha-Singh Atherosclerotic Peripheral Vascular Disease Symposium II: Executive Summary Circulation, December 16, 2008; 118(25): 2811 - 2825. [Full Text] [PDF]

				K. J. Rocha-Singh, A. C. Eisenhauer, S. C. Textor, C. J. Cooper, W. A. Tan, A. H. Matsumoto, K. Rosenfield, and for Writing Group 8 Atherosclerotic Peripheral Vascular Disease Symposium II: Intervention for Renal Artery Disease Circulation, December 16, 2008; 118(25): 2873 - 2878. [Full Text] [PDF]

				G. J Dubel and T. P Murphy The role of percutaneous revascularization for renal artery stenosis Vascular Medicine, May 1, 2008; 13(2): 141 - 156. [Abstract] [PDF]

				L. D. Dworkin and K. A. Jamerson Case Against Angioplasty and Stenting of Atherosclerotic Renal Artery Stenosis Circulation, January 16, 2007; 115(2): 271 - 276. [Full Text] [PDF]

				L. D. Dworkin Controversial Treatment of Atherosclerotic Renal Vascular Disease: The Cardiovascular Outcomes in Renal Atherosclerotic Lesions Trial Hypertension, September 1, 2006; 48(3): 350 - 356. [Full Text] [PDF]

				M. Chonchol and S. Linas Diagnosis and Management of Ischemic Nephropathy Clin. J. Am. Soc. Nephrol., March 1, 2006; 1(2): 172 - 181. [Full Text] [PDF]

				K. D.C., L. D.F., W. J., H. D., Y. X, T. J., B. K., S. M., D. P., L. R., et al. Accessory Renal Arteries--Mostly, But Not Always, Innocuous: Renin-Dependent Hypertension Caused by Nonfocal Stenotic Aberrant Renal Arteries--Proof of a New Syndrome. Hypertension 46: 380-385, 2005 J. Am. Soc. Nephrol., January 1, 2006; 17(1): 3 - 11. [Full Text] [PDF]

				H. Fujii, S. Nakamura, S. Kuroda, F. Yoshihara, H. Nakahama, T. Inenaga, H. Ueda-Ishibashi, C. Yutani, and Y. Kawano Relationship between renal artery stenosis and intrarenal damage in autopsy subjects with stroke Nephrol. Dial. Transplant., January 1, 2006; 21(1): 113 - 119. [Abstract] [Full Text] [PDF]

				R. A. Velliquette, T. O'Connor, and R. Vassar Energy Inhibition Elevates {beta}-Secretase Levels and Activity and Is Potentially Amyloidogenic in APP Transgenic Mice: Possible Early Events in Alzheimer's Disease Pathogenesis J. Neurosci., November 23, 2005; 25(47): 10874 - 10883. [Abstract] [Full Text] [PDF]

				V. D. Garovic and S. C. Textor Renovascular Hypertension and Ischemic Nephropathy Circulation, August 30, 2005; 112(9): 1362 - 1374. [Full Text] [PDF]

				A. Losito, R. Errico, P. Santirosi, T. Lupattelli, G. B. Scalera, and L. Lupattelli Long-term follow-up of atherosclerotic renovascular disease. Beneficial effect of ACE inhibition Nephrol. Dial. Transplant., August 1, 2005; 20(8): 1604 - 1609. [Abstract] [Full Text] [PDF]

				A. R. Chade, A. Lerman, and L. O. Lerman Kidney in Early Atherosclerosis Hypertension, June 1, 2005; 45(6): 1042 - 1049. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673